Maxim Group analyst Jason McCarthy maintained a Buy rating on BioLife Solutions (BLFS) yesterday and set a price target of $26.00. The company’s shares closed last Monday at $14.59.
According to TipRanks.com, McCarthy ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -22.0% and a 25.3% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Hancock Jaffe Laboratories, Lineage Cell Therapeutics, and Actinium Pharmaceuticals.
Currently, the analyst consensus on BioLife Solutions is a Strong Buy with an average price target of $24.75.
See today’s analyst top recommended stocks >>
BioLife Solutions’ market cap is currently $296.8M and has a P/E ratio of 107.68. The company has a Price to Book ratio of 5.96.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BioLife Solutions, Inc. engages in the development, manufacture, and marketing of biopreservation tools for cells and tissues. Its product offerings include proprietary hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs; generic blood stem cell freezing and cell thawing media products; and custom product formulation and custom packaging services. The company was founded by Boris Rubinsky in 1998 and it is headquartered in Bothell, WA.
